Tests of a promising new gene therapy to treat Alzheimer’s disease are moving to the phase II level, bringing the reversal of dementia damage one step closer to becoming a real medical possibility. Developed by scientists in The Memory Disorders Program at Georgetown University, CERE-110 is a virus engineered with the gene encoding nerve growth factor. The virus is injected directly into the affected parts of the brain through holes surgically drilled into the patient’s skull.
Loading ...
Groundbreaking Alzheimer's Gene Therapy Trial Moves Ahead
Posted by: Pam Baker September 25, 2009 09:26 AMTests of a promising new gene therapy to treat Alzheimer’s disease are moving to the phase II level, bringing the reversal of dementia damage one step closer to becoming a real medical possibility. Developed by scientists in The Memory Disorders Program at Georgetown University, CERE-110 is a virus engineered with the gene encoding nerve growth factor. The virus is injected directly into the affected parts of the brain through holes surgically drilled into the patient’s skull.